NCT00858936 - Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Coronary Artery Bypass Surgery

Interventions

DRUG

IK-1001

6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours

DRUG

Normal Saline

6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours

Trial Locations (8)

Alfred Hospital, Melbourne

Austin Hospital, Heidelberg

Ashford Hospital, Ashford

Flinder Medical Center, Bedford Park

St. Vincents Hospital, Melbourne

Boniface General Hospital, Winnepeg

Royal Victoria Hospital - MUHC, Montreal

Jewish General Hospital, Montreal